HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Taking “Risk-Based Approach” To Sequestration Cuts

This article was originally published in The Tan Sheet

Executive Summary

The agency will try to manage $319 million in potential funding reductions in a way that minimizes negative effects on health and safety, Commissioner Hamburg tells the Science Board, but significant layoffs seem unavoidable if sequestration is enacted.

You may also be interested in...



Sequestration Could Drive An FDA Resources Review

FDA and advocates wait to see how an estimated 7.8% budget cut would be implemented, if enacted. Former agency officials say sequestration could lead to hiring freezes and program delays.

FDA Considers New Regulatory Pathways For Some Cellular Products

The US agency is re-evaluating its criteria for certain human cells, tissues and cellular and tissue-based products (HCT/Ps) that are not ideally regulated as BLAs. A 2014 guidance on cord blood products could serve a template, industry suggests.

US FDA To Explore New Regulatory Pathways For Some Cellular Products

Agency re-evaluating criteria for certain human cells, tissues and cellular and tissue-based products (HCT/Ps) that are not ideally regulated as BLAs; industry suggests a 2014 guidance which created an alternative pathway for cord blood products could serve as potential template.

Topics

UsernamePublicRestriction

Register

RS133956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel